Literature DB >> 12235244

Primaquine-induced hemolytic anemia: effect of 6-methoxy-8-hydroxylaminoquinoline on rat erythrocyte sulfhydryl status, membrane lipids, cytoskeletal proteins, and morphology.

Laura J C Bolchoz1, Jason D Morrow, David J Jollow, David C McMillan.   

Abstract

Previous studies have shown that 6-methoxy-8-hydroxylaminoquinoline (MAQ-NOH), an N-hydroxy metabolite of the antimalarial drug, primaquine, is a direct-acting hemolytic agent in rats. To investigate the mechanism underlying this hemolytic activity, the effects of hemotoxic concentrations of MAQ-NOH on rat erythrocyte sulfhydryl status, membrane lipids, skeletal proteins, and morphology have been examined. Treatment of rat erythrocytes with a TC(50) concentration of MAQ-NOH (350 microM) caused only a modest and transient depletion of reduced glutathione (GSH) (~30%), which was matched by modest increases in the levels of glutathione disulfide and glutathione-protein mixed disulfides. Lipid peroxidation, as measured by thiobarbituric acid-reactive substances and F(2)-isoprostane formation, was induced in a concentration-dependent manner by MAQ-NOH. However, the formation of disulfide-linked hemoglobin adducts on membrane skeletal proteins and changes in erythrocyte morphology were not observed. These data suggest that hemolytic activity results from peroxidative damage to the lipid of the red cell membrane and is not dependent on skeletal protein thiol oxidation. However, when red cell GSH was depleted (>90%) by titration with diethyl maleate, hemolytic activity of MAQ-NOH was markedly enhanced. Of interest, exacerbation of hemotoxicity was not matched by increases in lipid peroxidation, but by the appearance of hemoglobin-skeletal protein adducts. Collectively, the data are consistent with the concept that MAQ-NOH may operate by more than one mechanism; one that involves lipid peroxidation in the presence of normal amounts of erythrocytic GSH, and one that involves protein oxidation in red cells with low levels of GSH, such as are seen in individuals with glucose-6-phosphate dehydrogenase deficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235244     DOI: 10.1124/jpet.102.036921

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Correlations among Anaplasma marginale parasitemia and markers of oxidative stress in crossbred calves.

Authors:  Ujjwal Kumar De; Sahadeb Dey; Partha Sarathi Banerjee; Monalisa Sahoo
Journal:  Trop Anim Health Prod       Date:  2011-08-13       Impact factor: 1.559

2.  Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Warunee Hanpithakpong; Nicholas P J Day; Nicholas J White; Joel Tarning
Journal:  Malar J       Date:  2022-06-03       Impact factor: 3.469

3.  Lipid peroxidation and antioxidant enzymes activity in Plasmodium vivax malaria patients evolving with cholestatic jaundice.

Authors:  Camila Fabbri; Rita de Cássia Mascarenhas-Netto; Pritesh Lalwani; Gisely C Melo; Belisa M L Magalhães; Márcia A A Alexandre; Marcus V G Lacerda; Emerson S Lima
Journal:  Malar J       Date:  2013-09-10       Impact factor: 2.979

4.  An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia.

Authors:  Rithea Leang; Naw Htee Khu; Mavuto Mukaka; Mark Debackere; Rupam Tripura; Soy Ty Kheang; Say Chy; Neeraj Kak; Philippe Buchy; Arnaud Tarantola; Didier Menard; Arantxa Roca-Felterer; Rick M Fairhurst; Sim Kheng; Sinoun Muth; Song Ngak; Arjen M Dondorp; Nicholas J White; Walter Robert John Taylor
Journal:  BMC Med       Date:  2016-10-27       Impact factor: 8.775

5.  The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians.

Authors:  Lek Dysoley; Saorin Kim; Sergio Lopes; Nimol Khim; Steven Bjorges; Samphornarann Top; Chea Huch; Huy Rekol; Nelli Westercamp; Mark M Fukuda; Jimee Hwang; Arantxa Roca-Feltrer; Mavuto Mukaka; Didier Menard; Walter R Taylor
Journal:  BMC Infect Dis       Date:  2019-03-12       Impact factor: 3.090

Review 6.  Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.

Authors:  Amin Gasmi; Massimiliano Peana; Sadaf Noor; Roman Lysiuk; Alain Menzel; Asma Gasmi Benahmed; Geir Bjørklund
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-30       Impact factor: 4.813

7.  The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.

Authors:  Brandon S Pybus; Sean R Marcsisin; Xiannu Jin; Gregory Deye; Jason C Sousa; Qigui Li; Diana Caridha; Qiang Zeng; Gregory A Reichard; Christian Ockenhouse; Jason Bennett; Larry A Walker; Colin Ohrt; Victor Melendez
Journal:  Malar J       Date:  2013-06-20       Impact factor: 2.979

8.  Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.

Authors:  Sim Kheng; Sinoun Muth; Walter R J Taylor; Narann Tops; Khem Kosal; Khon Sothea; Phum Souy; Saorin Kim; Chuor Meng Char; Chan Vanna; Po Ly; Pascal Ringwald; Virak Khieu; Alexandra Kerleguer; Pety Tor; John K Baird; Steven Bjorge; Didier Menard; Eva Christophel
Journal:  BMC Med       Date:  2015-08-25       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.